Determinants of primaquine and carboxyprimaquine exposures in children and adults with

***Plasmodium vivax* malaria**

Running title: **Primaquine exposures in vivax malaria**

Cindy S Chu[1,2], James A Watson[2,3,*], Aung Pyae Phyo[1], Htun Htun Win[1], Widi Yotyingaphiram[1], Suradet

Thinraow[1], Nay Lin Soe[1], Aye Aye Aung[1], Pornpimon Wilaisrisak[1], Kanokpich Puaprasert[4], Mallika Imwong[4],

Warunee Hanpithakpong[3], Daniel Blessborn[2,3], Joel Tarning[2,3], Stéphane Proux[1], Clare Ling[1,2], Francois H

Nosten[1,2], Nicholas J White[2,3]

[1] Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical

Medicine, Mahidol University, Mae Sot, Thailand

[2] Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of

Oxford, Oxford, UK

[3] Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,

Bangkok, Thailand

[4] Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol

University, Bangkok, Thailand.

Keywords: *Plasmodium vivax*, primaquine, pharmacokinetics, relapse, chloroquine,

dihydroartemisinin-piperaquine

Corresponding author: james@tropmedres.ac

Abstract

Background

Primaquine is the only widely available drug for radical cure of *Plasmodium vivax* malaria. There

is uncertainty whether the pharmacokinetic properties of primaquine are altered significantly in

childhood or not.

Methods

Glucose-6-phosphate dehydrogenase normal patients with uncomplicated *P. vivax* malaria were

randomized to receive either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine

(dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine; plus either 0.5 mg

base/kg/day for 14 days or 1 mg/kg/day for 7 days. Pre-dose day 7 venous plasma

concentrations of chloroquine, desethylchloroquine, piperaquine, primaquine and

carboxyprimaquine were measured. Methemoglobin levels were measured on days 1, 4, 7.

Results

Day 7 primaquine and carboxyprimaquine concentrations were available for 641 patients. After

adjustment for the primaquine mg/kg daily dose, day of sampling, partner drug, and fever

clearance, there was a significant non-linear relationship between age and trough primaquine

and carboxyprimaquine concentrations, and day methemoglobin levels. Compared to adults 30

years of age, children 5 years of age had trough primaquine concentrations 0.55 (95% CI: 0.39-

0.78) fold lower, trough carboxyprimaquine concentrations 0.43 (95% CI: 0.34- 0.55) fold lower,

and day 7 methemoglobin levels 0.87 (95% CI: 0.58-1.27) fold lower. Increasing concentrations

of piperaquine and chloroquine and poor metabolizer *CYP 2D6* alleles were also associated with

higher day 7 primaquine and carboxyprimaquine concentrations. Increased methemoglobin

concentrations were associated with a lower risk of recurrence.

Conclusion

Young children have lower primaquine and carboxyprimaquine exposures, and lower levels of

methemoglobinemia, than adults. Young children may need higher weight adjusted primaquine

doses than adults.

Introduction

Primaquine is used both for radical cure of *Plasmodium vivax* and *Plasmodium ovale* malaria and as a single dose gametocytocide in *Plasmodium falciparum* malaria (1). Although the slowly eliminated 8-aminoquinoline tafenoquine has been registered in a few countries for use in adults, primaquine is by far the most widely used drug in this class. There is uncertainty whether or not children have lower exposures to primaquine and its bioactive metabolites than adults for the same weight adjusted doses, and thus whether they should receive higher doses than currently recommended (2–5). Primaquine is combined with either an artemisinin combination treatment (ACT) or chloroquine to prevent relapse of vivax or ovale malaria (radical cure) (1). Primaquine is a pro-drug requiring metabolism to bioactive metabolites mainly via the liver cytochrome P450 isoenzyme *CYP 2D6* (6). The prevalence of intermediate and non-functioning *CYP 2D6* alleles is over 50% in some populations, particularly in Asians (7–9). Decreased *CYP 2D6* function, resulting from intermediate or poor metabolizer genotypes, potentially lowers radical cure efficacy (10, 11).

Chloroquine has been the first-line treatment for the blood stages of *P. vivax* malaria for over 70 years (1). High grade resistance remains confined to Oceania and Indonesia (12) but, in the last decade, low grade chloroquine resistance, manifest by earlier appearance of relapses, has been reported increasingly in other locations. Piperaquine (a slowly eliminated bisquinoline), combined with dihydroartemisinin, is a well-tolerated and highly efficacious ACT which provides an excellent alternative blood stage treatment for *P. vivax* malaria (13). This open label two-way randomized controlled trial conducted on the Thailand-Myanmar border showed previously that a 7-day high dose primaquine regimen (1 mg/kg/day) , combined either with chloroquine or

dihydroartemisinin-piperaquine, was non-inferior to the standard 14-day (0.5 mg/kg/day)

regimen (14). This study allowed investigation of the pharmacokinetic properties of primaquine

in adults and children, characterization of the determinants of drug exposures, and correlation

with therapeutic outcomes.

Methods

Clinical trial

This study was conducted by the Shoklo Malaria Research Unit (SMRU), which is located on the

northwest Thailand-Myanmar border. Full details of the study have been reported previously

(14). In brief, patients who presented to an outpatient clinic with microscopy confirmed

uncomplicated *P. vivax* mono-infections were enrolled if they were $\geq$ 6 months old, and if they

were glucose-6-phosphate dehydrogenase (G6PD) normal by the fluorescent spot test. Patients

were excluded if they were pregnant or breastfeeding an infant $\leq$ 6 months, had a hematocrit

$\leq$25%, or received a blood transfusion within 3 months. Written informed consent was obtained

from patients or from parents or carers of children below 18 years old.

Patients were randomized 1:1:1:1 to each of the following groups:

1. Chloroquine (10 mg base/kg on the first two days of treatment, then 5 mg base/kg on day

3; Remedica, Ltd., Cyprus) and primaquine (1 mg base/kg/day for 7 days; Government

Pharmaceutical Organization, Thailand)

2. Chloroquine as above and primaquine (0.5 mg base/kg/day for 14 days)

3. Dihydroartemisinin-piperaquine (dihydroartemisinin 7 mg/kg and piperaquine 55 mg/kg

for 3 days; Guilin Pharmaceutical company, China) and primaquine (1 mg base/kg/day for

7 days)

4. Dihydroartemisinin-piperaquine as above plus primaquine (0.5 mg base/kg/day for 14

days)

Food and drink were given before drug administration. Patients were assessed daily while on

treatment. Methemoglobin was measured either daily or on days 1, 3, 6 and 13, and additionally

on day 10 in the primaquine 14-day groups, using a transcutaneous pulse oximeter (Masimo

Radical-7®). One recruitment clinic did not have access to a transcutaneous oximeter, so 80

study patients did not have methemoglobin measurements. All drug doses were supervised.

A venous blood sample for antimalarial drug levels was taken before drug administration on day

6 (the 7th day of treatment) +/- 2 days, and plasma was separated. Patients were followed at

weeks 2 and 4, and then every 4 weeks until 52 weeks. If there was a *P. vivax* recurrence then a

venous plasma blood sample for drug levels was taken again. Standard high dose primaquine (0.5

mg/kg/day for 14 days) and chloroquine were given for the treatment of recurrences. Follow-up

was re-started as if newly recruited and day 6 sampling for drug levels was collected again. The

total study duration was 52 weeks from enrolment.

Drug measurements

Chloroquine/desethylchloroquine, piperaquine, and primaquine/carboxyprimaquine plasma

concentrations were measured using three validated liquid chromatography (LC) – tandem mass

spectrometry (MS/MS) methods (15–17). The lower limits of quantification (LLOQ) were set to

1.4, 1.5, 1.14 and 4.88 ng/mL for chloroquine/desethylchloroquine, piperaquine, primaquine and

carboxyprimaquine, respectively. All three quantification methods were validated according to

regulatory standards and three levels of quality control samples were analyzed in triplicate within

each batch of clinical samples. Total imprecision (i.e. relative standard deviation) for all quality

control samples was below 10% during drug quantification.

CYP 2D6 genotyping

We carried out a nested case-control study to assess the effect of *CYP 2D6* polymorphisms on

recurrent vivax malaria. Cases were all patients with a recorded recurrent episode of vivax

malaria during follow-up and controls were a set of patients matched by age and sex (total of

n=154 patients). The *CYP 2D6* gene duplications/multiplications and gene deletions were

determined by extra-long range polymerase chain reaction (XL-PCR) using a previously published

protocol (18). The functional *CYP 2D6* and nonfunctional *CYP2D8* and *CYP2D7* genes were then

differentiated by intron 2 sequencing (INT2). For a subset of samples, the variants *2, *4, *5, *10,

*35, and *36 were identified with rapid identification of four polymorphic loci by allele-specific

oligonucleotide probes using real-time SNPs genotyping. From the *CYP 2D6* genotyping result the

CYP 2D6 activity score was obtained (15, 19–21).

Ethics approval

This study was approved by both the Mahidol University Faculty of Tropical Medicine Ethics

Committee (MUTM 2011-043, TMEC 11-008) and the Oxford Tropical Research Ethics

Committee (OXTREC 17-11) and was registered at ClinicalTrials.gov (NCT01640574).

Statistical analysis

All drug concentrations were analyzed on the log base 10 scale. Three main generalized additive

linear regression models were fitted to the $\log_{10}$ primaquine day 7 concentrations; the $\log_{10}$

carboxyprimaquine concentrations; and the $\log_{10}$ carboxyprimaquine to primaquine ratios. We

used the following predictors age (years), mg/kg daily dose of primaquine, study arm (DHA-

piperaquine versus chloroquine), fever clearance time (days), and days since start of primaquine

dosing (6 versus 4). A smooth spline term with 3 degrees of freedom was used to estimate non-

linear effects of age. Individual random intercept terms were specified to account for multiple

day 7 measurements in the same patient. To assess any residual effect of *CYP 2D6* diplotypes, we

fitted linear regression models to the model residual concentrations with the *CYP 2D6* activity

score as a linear predictor. To estimate the effect of the partner drug concentrations (not

available for every day 7 measurement), we fitted separate generalized additive regression

models to the primaquine and carboxyprimaquine $\log_{10}$ concentrations with either the $\log_{10}$

chloroquine+desethychloroquine (designated as 'chloroquine' in the remainder of the paper)

concentration or the $\log_{10}$ piperaquine concentration as additional predictors.

We fitted a generalized additive regression model to the day 7 blood methemoglobin

concentrations (expressed as a percentage of the hemoglobin concentration) with age, mg/kg

daily dose of primaquine, study arm (DHA-piperaquine versus chloroquine), fever clearance time

(days), and days since start of primaquine dosing as predictors. A spline term with 3 degrees of

freedom was fit to age. Secondary models included the *CYP 2D6* activity score (available only for

a subset of patients) as an additional covariate, both on the linear scale and as a binary covariate

($\leq$0.5 versus >0.5). The activity score has an arbitrary scale so it is unclear how best to encode it

in regression models (i.e. an activity score of 2 versus 1 is not the same as 1 versus 0).

We fitted Cox proportional hazard models to the time to first recurrence (right censored event

for patients who did not have a recurrence during follow-up), with continuous predictors: age,

partner schizonticidal drug (chloroquine versus piperaquine), and either the $\log_{10}$ primaquine or

the $\log_{10}$ carboxyprimaquine day 7 concentration (they are highly co-linear so we fitted two

separate models). Additional models included the day 7 methemoglobin levels as an additional

predictor (this was not measured in all patients).

The generalized additive models were fitted in R version 4.0.2 using the package *mgcv* version

1.8. The Cox proportional hazard model used the *survival* package version 3.2. Code in the form

of an RMarkdown script along with all analyzed data are available on an accompanying github

repository for full reproducibility (https://github.com/jwatowatson/Primaquine_day7).

Results

Between February 2012 and July 2014, 680 patients with uncomplicated acute *P. vivax* malaria

were enrolled. A total of 641 patients had at least one day 7 plasma primaquine and

carboxyprimaquine concentration measured, either during the enrollment episode or during a

recurrent *P. vivax* episode (there were a total of 720 episodes with day 7 concentrations including

patients with multiple episodes). For 692 of these day 7 concentrations, the corresponding

plasma chloroquine or piperaquine concentration was also available (measured from the same

blood sample). We excluded three drug measurements from three patients who stopped

primaquine before day 7 (resulting in a total of 717 day 7 measurements included in the analysis).

In total, 71 of the patients with measured primaquine and carboxyprimaquine concentrations

were 6 to ≤10 years of age (median weight 20kg, range 13-30kg), and 34 were ≤5 years of age

(median weight 14kg, range 8-20kg) (Table 1). Three patients were less than 3 years old, and the

youngest was 1 year 6 months old. Fever and parasite clearance were similar across all age

groups. The proportion of patients with microscopy detected gametocytemia was higher in the

older age groups >10 years.

Effect of age

After adjustment for the daily mg/kg primaquine dose, the number of days of dosing, the fever

clearance times, and the partner drug (piperaquine versus chloroquine), there was a significant

non-linear association between age and day 7 primaquine trough concentration ($p=10^{-9}$ for the

smooth spline term fit to age) and day 7 carboxyprimaquine trough concentration ($p=10^{-29}$ for

the smooth spline term fit to age) (Figure 1). For both primaquine and carboxyprimaquine,

increasing age was correlated with higher trough levels. The strongest effect was seen for the

carboxyprimaquine trough levels. The ratio of carboxyprimaquine to primaquine was thus also

associated with age, with an approximate doubling when comparing patients aged $\leq$5 years

versus patients 30 years or older (Figure 1).

Effect of partner drug

Previously healthy volunteer studies reported that co-administration of piperaquine and

chloroquine both increased exposures to primaquine and carboxyprimaquine (15, 16, 22). In this

study of patients with vivax malaria, a ten-fold increase in the chloroquine day 7 concentration

was associated with a 2.2 fold increase in day 7 primaquine concentrations (95% CI: 1.7 to 2.9;

$p=0.004$), and a 1.8 fold increase in day 7 carboxyprimaquine concentration (95% CI: 1.5 to 2.2;

$p=0.001$). A ten-fold increase in the piperaquine day 7 concentration was associated with a 2.5

fold increase in primaquine concentration (95% CI: 1.9 to 3.3; p=0.0008), and a 2.7 fold increase

in carboxyprimaquine concentration on day 7 (95% CI: 2.2 to 3.3; $p=10^{-7}$). For both chloroquine

and   piperaquine,   there   was   no   statistically   significant   effect   on   the

carboxyprimaquine/primaquine ratios.

Effect of *CYP 2D6* genotypes

CYP 2D6 genotypes were determined in 154 patients. The estimated *CYP 2D6* allele frequencies

in this population were as follows: 25% for *1; 23% for *2; 2% for *4; 10% for *5; 38% for *10;

0.5% for *39; and 1% for *36. Alleles *4, *5, and *36 are considered null-metabolizer alleles

(activity score of 0); *10 is a poor metabolizer allele (activity score of 0.25); and *1 and *39 are

normal metabolizer alleles (activity score of 1). In total, there were 3 patients with an activity

score of 0 (non-metabolizers) and 36 patients with activity scores of either 0.25 or 0.5 (poor

metabolizers). For primaquine day 7 plasma concentrations, model residuals (defined as the

observed concentration minus the predicted concentration, both on the log scale where the

model is based on age, mg/kg dose and partner drug), were significantly associated with the

genotype-defined *CYP 2D6* enzyme activity scores (Figure 2; p=0.001). Patients with low *CYP 2D6*

activity scores had, on average, higher observed concentrations of primaquine than predicted

(i.e. positive residuals), whereas patients with normal activity scores had lower concentrations

than expected (i.e. negative residuals). For plasma carboxyprimaquine concentrations, a trend in

the same direction was observed but the effect was substantially smaller and was not significant

(p=0.1).

Methemoglobinemia and hemolysis

Primaquine causes predictable methemoglobinemia. As reported previously methemoglobin

concentrations rose over the first week of primaquine treatment, and then plateaued in the 14-

day primaquine groups. The day 7 values were usually the peak recorded values

(Supplementary Figure 1). Methemoglobin (expressed as a percentage of the hemoglobin

concentration) was lower in children than in young adults ($p<10^{-16}$ for a spline term fit to age in

a generalized additive regression model, Figure 3A), and was lower in patients with loss of

function *CYP 2D6* polymorphisms (absolute decrease of 1.2 percentage points in the mean day

7 methemoglobin level in patients with an activity score $\leq$ 0.5 compared to patients with an

activity score > 0.5; 95% CI: 0.1-2.3%, *p*=0.04). Day 7 methemoglobin levels were associated

with both primaquine and carboxyprimaquine day 7 plasma concentrations. A ten-fold increase

in primaquine day 7 concentration was associated with an absolute increase of 0.7 percentage

points in day 7 methemoglobin (95% CI: 0.14-1.23), and a ten-fold increase in

carboxyprimaquine concentration was associated with an absolute increase of 1.2 percentage

points in day 7 methemoglobin levels (95% CI: 0.5 – 2.0). Four patients stopped primaquine

because of elevated methemoglobin levels and associated symptoms. Two of these patients

stopped on day 5 and thus had low day 7 primaquine and carboxyprimaquine levels as the day

6 primaquine dose was not administered. One of these patients had a recorded methemoglobin

level of 20.9% on day 6 followed by 18.1% on day 7. The other three patients had peri-oral

cyanosis (blue lips). Their peak recorded methemoglobin levels were between 10 and 12%.

There was no relationship between age and hemolysis defined as the percentage drop in

hematocrit between baseline and day 7 (Figure 3B).

Primaquine exposure and *P. vivax* recurrence

We did an exploratory analysis of the relationship between primaquine exposures and times to

the first *P. vivax* recurrence. A total of 564 patients had recorded day 7 drug levels and

methemoglobin levels, and 70 had at least one recurrence during follow-up. After adjusting for

age and partner drug, day 7 concentrations of primaquine and carboxyprimaquine were not

associated with the risk of recurrence, but a 1% absolute increase in day 7 methemoglobin was

associated with a hazard ratio for recurrence of 0.9 (95% CI: 0.85-0.99, p=0.02). Two of the

three patients with a *CYP 3D6* activity score of 0 had a *P. vivax* recurrence, and one of them had

2 recurrences (the interval between recurrences was >65 days).

Discussion

Radical cure of *P. vivax* malaria is necessary to prevent relapses. Relapses are a major cause of

morbidity and developmental delay in children living in endemic areas, so optimization of dosing

is critical in this population. The higher *P. vivax* relapse rates in children compared with adults

living in endemic areas observed in some studies (23) are attributed usually to lower levels of

immunity, but lower drug exposures could also be a contributory factor. For many antimalarial

drugs, exposures in children are lower than in adults and an increase in the weight adjusted

dosing is needed (1). The limited pharmacokinetic evidence to date for primaquine does not

provide a clear picture, with a study from Papua New Guinea suggesting little difference between

adults and older children (2), whereas a study of single dose primaquine (used as a *P. falciparum*

gametocytocide) in Tanzania (3) and a study of primaquine for *P. vivax* radical cure in Brazil (4)

both suggested that younger children had lower exposures. Primaquine is metabolized rapidly

(elimination half-life ~5 hours) via monoamine oxidase to a biologically inert metabolite

carboxyprimaquine and, through a separate pathway, to several active hydroxylated metabolites

mainly via *CYP 2D6* (6, 24). Recent laboratory studies suggest that these unstable hydroxylated

metabolites are oxidized to quinoneimines generating local hydrogen peroxide - which is

parasiticidal.   The   quinoneimines   in   turn   are   substrates   for   cytochrome   P450

NADPH:oxidoreductase (POR or CPR) resulting in hydrogen peroxide accumulation and

augmenting the parasiticidal effect (25). These reactions mediate the antimalarial therapeutic

effects, and also the oxidant hemolytic adverse effects. There is also evidence for synergy

between the 8-aminoquinolines and other quinoline antimalarials in blood stage activity (26, 27).

The 8-aminoquinolines have innate schizonticidal activity as well as in radical curative activity and

4-aminoquinoline antimalarials increase primaquine concentrations (15, 16). Unfortunately,

although the metabolic pathway to the production of the active primaquine metabolites has

been characterized ex-vivo, no validated measure of their concentrations, or of their more stable

metabolites, in whole blood, plasma, or urine has yet been correlated with antimalarial

therapeutic responses in-vivo. Thus, measurement of primaquine and carboxyprimaquine

concentrations does not provide a direct correlate of antimalarial activity. Furthermore, because

the apparent volume of distribution of carboxyprimaquine is not known, the proportion of parent

drug that passes through this inactive metabolic pathway cannot be estimated.

This large study of day 7 "trough" primaquine and carboxyprimaquine plasma concentrations

shows clearly that exposures to both parent compound and inactive metabolite are lower in

children than in adults. This is unlikely to be explained by lower bioavailability as primaquine is

generally well absorbed, the children in the study were clinically well by seven days after starting

treatment (14), all doses were observed and only 7 children ≤10 years old (≤27kg) vomited. It

presumably reflects either larger primaquine (and carboxyprimaquine) distribution volumes, or

increased clearance, or both. The lower ratio of carboxyprimaquine to primaquine in children

may also be explained by these age-related pharmacokinetic changes. Although a greater

diversion down the bioactive CYP pathway cannot be excluded - there is no convincing evidence

for augmented drug efficacy (no relationship with fever or parasite clearance time) or increased

hemolytic toxicity in children to support this. Furthermore, in this study, methemoglobinemia

was lower in children than in young adults, indicating that formation of oxidant metabolites was

reduced (28). The importance of *CYP 2D6* primaquine bioactivation in the generation of oxidant

metabolites was evidenced by the lower levels of methemoglobinemia in patients with loss of

function *CYP 2D6* polymorphisms. Together this evidence strongly suggests that children have

lower exposures to the biologically active metabolites of primaquine than do adults receiving the

same weight adjusted doses.

This study was sufficiently large that the influence of other covariates affecting primaquine

exposures could be examined. We have reported previously that co-administration of quinoline

or structurally related antimalarials increases primaquine and carboxyprimaquine concentrations

(15, 16). This was confirmed in this study. The effects on the parent compound of chloroquine

and piperaquine were similar whereas piperaquine had a larger effect on carboxyprimaquine. In

Asia loss of function *CYP 2D6* genetic polymorphisms (mainly the *10 allele) are common. In this

study low *CYP 2D6* activity scores (derived from the genotype) were associated with higher

primaquine levels and lower levels of methemoglobinemia as would be expected from reduced

metabolic conversion through this bioactivation pathway.

There are several limitations to this study. This analysis is limited to drug concentrations at one

time point during radical cure treatment providing a limited description of drug exposures. Very

young children are under-represented, and the analysis does not include any infants < 1 year old.

In addition, *CYP 2D6* genotyping was not performed in all patients.

There is no evidence that the adverse effects of primaquine are significantly worse in children

than adults. The main therapeutic implication of this large pharmacometric evaluation is that

children may require larger weight adjusted doses of primaquine than adults.

Funding

This work was supported by the Wellcome Trust [grant number 089179/Z/09/Z] to NJW. CSC, JW,

APP, JT, CL, FHN and NJW are supported by the Wellcome Trust [Programme grant number

089179]. CSC, JW, APP, JT, CL, FHN, and NJW are part of the Wellcome Trust Mahidol University

Oxford Tropical Medicine Research Programme funded by the Wellcome Trust.

Acknowledgements

This research was funded by The Wellcome Trust. A CC BY or equivalent license is applied to the

author accepted manuscript arising from this submission, in accordance with the grant's open

access conditions. The authors would like to thank the SMRU staff for their hard work in

running this study and the MORU Clinical Pharmacology Laboratory in Bangkok for their diligent

work in sample processing and drug measurements. Special appreciation goes to the

contributions of Htet Htet Chaw, Nwe Wah Lin, Thida Zin, Say Paw, Naw Eh Shee, Thu Lay Paw,

Rattanporn Raksapraidee, Moo Koo Paw, the data entry team headed by Jacher

Wiladphaingern, the logistics team, and the laboratory teams headed by Kanlaya Sriprawat and

Germana Bancone.

We would also like to thank the Data Safety and Monitoring Board: Bob Taylor, Charles Woodrow,

and Professor Nicholas Day for their time and commitment.

References

1. World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd Edition. World Health Organization, Geneva.

2. Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, Waita E, Batty KT, Siba P, Mueller I, Davis TME, Betuela I. 2014. Pharmacokinetic properties of single-Dose primaquine in papua new guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. Antimicrob Agents Chemother 58:432–439.

3. Gonçalves BP, Pett H, Tiono AB, Murry D. 2017. Age, weight, and CYP2D6 genotype are major determinants of primaquine pharmacokinetics in African children. Antimicrob Agents Chemother Agents Chemother 61:e02590-16.

4. Vieira MVDF, Matos Lopes TR, Mello AGNC, de Sena LWP, Commons RJ, Vieira JLF. 2020. Doses of primaquine administered to children with Plasmodium vivax according to an age-based dose regimen. Pathog Glob Health 114:388–392.

5. Gogtay N, Karande S, Kadam P, Momin S, Thatte U. 2021. Evaluation of pharmacokinetics of single-dose primaquine in undernourished versus normally nourished children diagnosed with Plasmodium vivax malaria in Mumbai. J Postgrad Med 67:75–79.

6. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard G a, Ockenhouse C, Bennett J, Walker L a, Ohrt C, Melendez V. 2013. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 12:e212.

7. Neafsey P, Ginsberg G, Hattis D, Sonawane B. 2009. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 12:334–361.

8. McGraw J, Waller D. 2012. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 8:371–382.

9. Puaprasert K, Chu C, Saralamba N, Day NPJ, Nosten F, White NJ, Dondorp AM, Imwong M. 2018.

Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen

population study. Malar J 17:427.

10. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC. 2013. Primaquine failure and cytochrome P-

450 2D6 in Plasmodium vivax malaria. N Engl J Med 369:1380–1381.

11. Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, Chand K, Gayatri A, Instiaty,

Soebianto S, Crenna-Darusallam C, Djoko D, Hasto BD, Meriyenes D, Wesche D, Nelwan EJ,

Sutanto I, Sudoyo H, Setiabudy R. 2018. Association of Impaired Cytochrome P450 2D6 Activity

Genotype and Phenotype with Therapeutic Efficacy of Primaquine Treatment for Latent

Plasmodium vivax Malaria. JAMA Netw Open 1:e181449.

12. Price RN, von Seidlein L, Valecha N, Nosten FH, Baird JK, White NJ. 2014. Global extent of

chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis

14:982–91.

13. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, Auburn S,

Chand K, Chau NH, Cheah PY, Dong LT, Dhorda M, Degaga TS, Devine A, Ekawati LL, Fahmi F,

Hailu A, Hasanzai MA, Hien TT, Khu H, Ley B, Lubell Y, Marfurt J, Mohammad H, Moore KA,

Naddim MN, Pasaribu AP, Pasaribu S, Promnarate C, Rahim AG, Sirithiranont P, Solomon H,

Sudoyo H, Sutanto I, Thanh NV, Tuyet-Trinh NT, Waithira N, Woyessa A, Yamin FY, Dondorp A,

Simpson JA, Baird JK, White NJ, Day NP, Price RN. 2019. Short-course primaquine for the radical

cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority

trial. Lancet 394:929–938.

14. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, Thinraow S, Wilairisak P,

Raksapraidee R, Carrara VI, Paw MK, Wiladphaingern J, Proux S, Bancone G, Sriprawat K, Lee SJ,

Jeeyapant A, Watson JA, Tarning J, Imwong M, Nosten F, White NJ. 2018. Chloroquine versus

dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or

14 days in Plasmodium vivax malaria. Clin Infect Dis 68:1311–1319.

15.   Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W,

Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NPJ, White NJ. 2014. Open-Label Crossover

Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai

Subjects. Antimicrob Agents Chemother 58:7340–7346.

16.   Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ,

Hanpithakpong W, Hanboonkunupakarn B, Day NPJ, Ashley E a, White NJ. 2014. Pharmacokinetic

interactions between primaquine and chloroquine. Antimicrob Agents Chemother 58:3354–3359.

17.   Kaewkhao K, Chotivanich K, Winterberg M, Day NP, Tarning J, Blessborn D. 2019. High sensitivity

methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS.

Bioanalysis 11:333–347.

18.   Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, LLerena A. 2005. Development of a

PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential

use. Biotechniques 39:571–574.

19.   Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity

score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol

Ther 83:234–242.

20.   Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling M V.,

Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A. 2020. Standardizing CYP2D6 Genotype to Phenotype

Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation

Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13:116–124.

21.   Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Heng TK, Nou S,

Arsanok M, Sriwichai S, Vanachayangkul P, Lin JT, Manning JE, Jongsakul K, Pichyangkul S,

Satharath P, Smith PL, Dysoley L, Saunders DL, Waters NC. 2020. Prevalence of CYP2D6

genotypes and predicted phenotypes in a cohort of cambodians at high risk for infections with

plasmodium vivax. Am J Trop Med Hyg 103:756–759.

22. Lee SJ, McGready RM, Fernandez C, Stepniewska K, Paw MK, Viladpai-Nguen SJ, Thwai KL,

Villegas L, Singhasivanon P, Greenwood BM, White NJ, Nosten FH. 2008. Chloroquine

pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol

64:987–992.

23. Luxemburger C, van Vugt M, Jonathan S, McGready RM, Looareesuwan S, White NJ, Nosten FH.

1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg

93:433–438.

24. Avula B, Tekwani BL, Chaurasiya ND, Fasinu P, Dhammika Nanayakkara NP, Bhandara Herath

HMT, Wang Y-H, Bae J-Y, Khan SI, Elsohly MA, McChesney JD, Zimmerman PA, Khan IA, Walker

LA. 2018. Metabolism of primaquine in normal human volunteers: investigation of phase I and

phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-

quadrupole time-of-flight mass spectrometry. Malar J 17:294.

25. Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL, Leung S, Miller AB,

Baker DA, Alano P, Paine MJI, Bhatia SN, O'Neill PM, Ward SA, Biagini GA. 2019. Antimalarial

activity of primaquine operates via a two-step biochemical relay. Nat Commun 10: e3226.

26. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation

of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med

46: 301-6.

27. Baird JK. 2019. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev 32:1–68.

28. Umbreit J. 2007. Methemoglobin--it's not just blue: a concise review. Am J Hematol 82:134–144.

Tables and Figures

Table 1. Patient characteristics at enrolment by age group

	Age group			
	≤5 years	6-10 years	11-15 years	≥16 years
	n=34	n=71	n=118	n=418
Chloroquine+Primaquine-7	8 (5%)	22 (13%)	29 (18%)	104 (64%)
Chloroquine+Primaquine-14	10 (6%)	18 (11%)	29 (18%)	103 (65%)
DHAP+Primaquine-7	7 (4%)	15 (10%)	37 (24%)	98 (62%)
DHAP+Primaquine-14	9 (6%)	16 (10%)	23 (14%)	113 (70%)
Median age years (IQR, range)	4 (3.2-5, 1.5-5)	8 (6-10, 5.1-10)	13 (12-14, 11-15)	28 (20-39, 16-63)
Median weight, kg (IQR, range)	14 (12-16, 8-20)	20 (16-23, 13-30)	35 (29-43, 21-57)	52 (47-56, 31-88)
Median Body Mass Index, kg/m^2 (IQR, range)	15 (14-16, 13-18)	14 (14-15, 11-18)	17 (15-18, 12-23)[1]	20 (19-22, 13-36)
History of fever, n (%)	34 (100%)	71 (100%)	118 (100%)	411 (98%)
Median temperature >37.5°C, (IQR, range)	37.5 (36.7-38.2, 36-40)	37.4 (36.8-38.2, 36-40.1)	37.6 (37-38.5, 36-40.9)[1]	37.3 (36.8-38.1, 36-40.9)
Fever clearance; days (range)	0 (0-4)	0 (0-3)	1 (0-2)	0 (0-4)
Geometric mean parasitemia, parasites/μL (range)	3096 (16-40,192)	3633 (16-221,056)	4886 (16-75,109)	3804 (16-816,400)
Parasite clearance, days (range)	2 (1-4)	2 (1-3)	2 (1-4)	2 (1-5)
Gametocytemia, n (%)	23 (68%)	56 (79%)	104 (88%)	352 (84%)
Median chloroquine level[a], ng/mL (range)	54.3 (6.4-115)	50.1 (27.3-138)	56.1 (27.6-161)	77.9 (26.9-248)
Median piperaquine level[a], ng/mL (range)	37.5 (15.3-109)	29.4 (10-7-78.2)	35.3 (7.7-131)	37 (7.3-181)
Median carboxyprimaquine level[a], ng/mL (range)	261 (29-1410)	406 (9-1590)	563 (40-2740)	793 (59-4710)
Median primaquine level[a], ng/mL (range)	3.5 (1.1-43.8)	3.8 (0.9-349)	5.2 (0.9-106)	6.9 (1-293)
Median carboxyprimaquine: primaquine ratio[a], (range)	86 (12-207)	97 (4-256)	98 (23-516)	106 (2-564)

Primaquine-7: primaquine dosing 1 mg/kg/day for 7 days

Primaquine-14: primaquine dosing 0.5 mg/kg/day for 14 days

Numeric superscript denotes the number of missing values

[a] Only data from the first episode are included

Legends to Figures

Figure 1: The effect of age on primaquine and carboxyprimaquine exposures in patients with acute vivax

malaria.

Panel A: age versus mg/kg primaquine daily dose;

Panel B: age versus the primaquine concentration on day 7;

Panel C: age versus the carboxyprimaquine concentration on day 7;

Panel D: age versus the ratio of the day 7 carboxyprimaquine to primaquine concentration.

The black lines show model fits using a generalized additive model with a smooth spline term for age

and adjusting for daily mg/kg dose; number of days of primaquine received, partner drug and fever

clearance time (dashed: mean predicted concentration for 1mg/kg daily; solid: mean predicted

concentration for 0.5 mg/kg daily).

Figure 2: The effect of *CYP 2D6* genotypes on primaquine and carboxyprimaquine exposure. The y-axis

shows the model residuals (observed minus predicted) for the main model of exposure (adjusting for

age, daily mg/kg primaquine dose, partner drug, and fever clearance time). The x-axis is the predicted

activity score from the *CYP 2D6* diplotype (20) . The thick black lines show a linear regression fit.

Figure 3: Age and drug exposure relationships with hemolysis and methemoglobinemia.

Panel A: Age and day 7 methemoglobin

Panel B: Age and the day 7 change in hematocrit from baseline.

Panel C: Day 7 methemoglobin and pre-dose primaquine concentrations

Panel D: Day 7 methemoglobin and pre-dose carboxyprimaquine concentrations

Supplementary Figure 1: Methemoglobin as function of the time since starting primaquine (black

circles: 0.5 mg/kg target dose for 14 days; red circles: 1 mg/kg target dose for 7 days). We added

random jitter to the time in days for visual clarity.

Figure 1

465
466   *Figure 2*

467
468

Figure 3

473   Supplementary Figure 1